Rock Springs Capital Management LP - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 23 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Rock Springs Capital Management LP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$1,381,000
-2.7%
1,500,0000.0%0.04%
+11.1%
Q1 2022$1,420,000
-2.5%
1,500,0000.0%0.04%
+5.9%
Q4 2021$1,456,000
+4.7%
1,500,0000.0%0.03%
+17.2%
Q3 2021$1,391,000
-2.7%
1,500,0000.0%0.03%
+3.6%
Q2 2021$1,429,000
-6.4%
1,500,0000.0%0.03%
-15.2%
Q1 2021$1,526,000
+7.5%
1,500,0000.0%0.03%
+10.0%
Q4 2020$1,420,000
+7.6%
1,500,0000.0%0.03%
-9.1%
Q3 2020$1,320,000
-9.6%
1,500,0000.0%0.03%
-17.5%
Q2 2020$1,460,000
+0.8%
1,500,0000.0%0.04%
-33.3%
Q1 2020$1,448,000
-7.0%
1,500,0000.0%0.06%
+22.4%
Q4 2019$1,557,000
+13.2%
1,500,0000.0%0.05%
-10.9%
Q3 2019$1,376,000
+6.7%
1,500,0000.0%0.06%
+17.0%
Q2 2019$1,290,000
-11.5%
1,500,0000.0%0.05%
-16.1%
Q1 2019$1,457,000
-5.8%
1,500,0000.0%0.06%
-23.3%
Q4 2018$1,547,000
-12.6%
1,500,0000.0%0.07%
+14.1%
Q3 2018$1,770,000
+18.7%
1,500,0000.0%0.06%
+12.3%
Q2 2018$1,491,000
-1.6%
1,500,0000.0%0.06%
-12.3%
Q1 2018$1,515,000
-7.9%
1,500,0000.0%0.06%
-13.3%
Q4 2017$1,645,000
-10.8%
1,500,0000.0%0.08%
-11.8%
Q3 2017$1,844,000
-9.3%
1,500,0000.0%0.08%
-17.5%
Q2 2017$2,032,000
+7.0%
1,500,0000.0%0.10%
-6.4%
Q1 2017$1,899,000
+10.9%
1,500,0000.0%0.11%
-4.3%
Q4 2016$1,713,0001,500,0000.12%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2021
NameSharesValueWeighting ↓
Context Capital Management, LLC 25,388$23,544,0002.40%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 49,675,000$46,013,0001.22%
DeepCurrents Investment Group LLC 33,824,000$31,165,0000.93%
Aequim Alternative Investments LP 13,920,000$12,909,0000.50%
Maven Securities LTD 14,280,000$14,280,0000.46%
Saltoro Capital, LP 1,350,000$1,252,0000.44%
Baupost Group 30,000,000$27,640,0000.25%
TENOR CAPITAL MANAGEMENT Co., L.P. 5,500,000$5,182,0000.12%
ZAZOVE ASSOCIATES LLC 1,250,000$1,163,0000.10%
HBK INVESTMENTS L P 22,500,000$20,832,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders